Scarica l'app Stockscreener
80.04
3.30%
-2.80
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$82.84
Aprire:
$82.47
Volume 24 ore:
4.92M
Relative Volume:
0.30
Capitalizzazione di mercato:
$209.34B
Reddito:
$63.92B
Utile/perdita netta:
$17.43B
Rapporto P/E:
11.65
EPS:
6.87
Flusso di cassa netto:
$18.10B
1 W Prestazione:
-5.43%
1M Prestazione:
-1.67%
6M Prestazione:
-20.47%
1 anno Prestazione:
-37.20%
Intervallo 1D:
$80.03
$82.48
Intervallo di 1 settimana:
$80.03
$85.83
Portata 52W:
$75.93
$134.63
Merck Co Inc Stock (MRK) Company Profile
Nome
Merck Co Inc
Settore
Industria
Telefono
908-740-4000
Indirizzo
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Confronta MRK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
80.09 | 209.34B | 63.92B | 17.43B | 18.10B | 6.87 |
|
LLY
Lilly Eli Co
|
789.35 | 737.81B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.62 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
189.41 | 340.25B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
67.17 | 277.97B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
112.45 | 222.45B | 53.22B | 12.86B | 14.85B | 6.39 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2025-02-18 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-02-10 | Downgrade | TD Cowen | Buy → Hold |
| 2025-01-08 | Downgrade | Truist | Buy → Hold |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-12-04 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-11 | Downgrade | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-03-11 | Downgrade | Societe Generale | Hold → Sell |
| 2024-01-04 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Buy |
| 2023-10-27 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Hold |
| 2023-04-13 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-03-28 | Downgrade | Societe Generale | Buy → Hold |
| 2023-03-13 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Iniziato | Jefferies | Buy |
| 2023-02-22 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-10-10 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-14 | Aggiornamento | Berenberg | Hold → Buy |
| 2022-07-06 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Ripresa | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-16 | Iniziato | Daiwa Securities | Neutral |
| 2021-12-13 | Downgrade | UBS | Buy → Neutral |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-12-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-29 | Downgrade | Citigroup | Buy → Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-01 | Aggiornamento | Argus | Hold → Buy |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-20 | Downgrade | Argus | Buy → Hold |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Ripresa | Bernstein | Outperform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-08-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-06-12 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-08-16 | Iniziato | SVB Leerink | Outperform |
| 2019-07-03 | Iniziato | Mizuho | Buy |
| 2019-05-28 | Iniziato | Goldman | Neutral |
| 2019-05-13 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Reiterato | Citigroup | Buy |
| 2018-10-09 | Ripresa | Guggenheim | Buy |
| 2018-04-23 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-04-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Reiterato | Leerink Partners | Mkt Perform |
| 2018-02-07 | Reiterato | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Merck Co Inc Borsa (MRK) Ultime notizie
Long-Term Investors in shares of Merck & Co., Inc. (NYSE: MRK) - openPR.com
Merck & Co Unusual Options Activity - Nasdaq
Is Merck & Co., Inc. (MRK) The Most Profitable Cheap Stock to Buy Now? - Yahoo Finance
Are Wall Street Analysts Bullish On Merck Stock? - Barchart.com
FDA Action Alert: GSK, Sanofi, Merck and More - BioSpace
Merck invests $1B in Wilmington facility to boost U.S. drug production amid tariff concerns - Audacy
Merck Expands Biomanufacturing with Staggering Investment in Wilmington - VISTA.Today
Merck & Co., Inc. SEC 10-Q Report - TradingView
Merck Stock Price | MRK Stock Quote, News, and History - markets.businessinsider.com
Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology - insights.citeline.com
Liver Cancer Treatment Market is expected to generate a revenue of USD 8.88 Billion by 2031, Globally, at 13.45% CAGR: Verified Market Research® - GlobeNewswire Inc.
Merck & Co., Inc. (MRK): Jim Cramer Agrees – “Merck’s A Good Company” - Insider Monkey
Jim Cramer Says He Likes Bristol-Myers Squibb (BMY) More Than Merck Due to Schizophrenia Drug - Yahoo Finance
Arvinas, Entrada cut staff; Merck builds US hub for Keytruda - BioPharma Dive
June 13th Options Now Available For Merck (MRK) - Nasdaq
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know - Yahoo Finance
AmacaThera and Merck Animal Health Announce Collaboration in Animal Health - Newswire.ca
Pharmaceutical company Merck to invest $1 billion in Delaware plant - The American Bazaar
Is Merck & Co. Inc. (MRK) the Best Dow Stock for the Next 12 Months? - Yahoo Finance
In Brief: Merck To Invest $1bn In New US Biologics Production - insights.citeline.com
Merck & Co courts Washington with Delaware build statement - The Pharma Letter
Merck Shareholder Drops Suit Against Execs Over Gardasil Demand - Bloomberg Law News
Merck & Co., Inc. (MRK): Among Billionaire Cliff Asness’ Stock Picks with Huge Upside Potential - Insider Monkey
Guggenheim Adjusts Merck & Co.'s Price Target to $108 From $115 - marketscreener.com
Guggenheim cuts Merck stock target to $108, keeps Buy rating By Investing.com - Investing.com India
Merck (MRK) Price Target Reduced by Guggenheim Analyst | MRK Sto - GuruFocus
Merck & Co. (MRK) Looks to New Cholesterol Drug as Keytruda Expiration Looms - TipRanks
Analysis of Cancer Immunotherapy Technologies and Global Markets to 2029 - GlobeNewswire Inc.
Merck plans to move manufacturing of its biggest drug, Keytruda, to a new US factory and lab in Delaware - The Daily Gazette
Merck breaks ground at Chestnut Run - WDEL.com
How To Put $100 In Your Retirement Fund Each Month With Merck Stock - Benzinga
Merck to invest $1 billion in new Delaware plant to boost US manufacturing - Reuters
Merck plans to bring Keytruda production to the US with $1B biologics factory - Endpoints News
Is Merck & Co., Inc. (MRK) the Worst-Performing Blue Chip Stock So Far in 2025? - Insider Monkey
Merck to build $1B biologics center in Wilmington - The Business Journals
Merck Begins Construction of $1 Billion Biologics Facility in Delaware - marketscreener.com
Merck to invest $1 billion in U.S. drug manufacturing plant - CBS News
Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware | MRK Stock News - GuruFocus
Merck (MRK) to Invest $1 Billion in Delaware Manufacturing Plant - GuruFocus
Merck Breaks Ground On New $1 Billion Biologics Center Of Excellence In Wilmington, Delaware - marketscreener.com
Merck (MRK) Commences Construction on Advanced Biologics Facilit - GuruFocus
Merck to build $1B Delaware plant to ensure domestic supply of Keytruda (MRK:NYSE) - Seeking Alpha
Stock Watch: Sanofi, Merck Open Windows Into Geopolitical Risks - insights.citeline.com
Merck to invest $1 billion in new US site - breakingthenews.net
Merck to invest $1 billion in new Delaware plant to boost US manufacturing, WSJ reports - marketscreener.com
Merck To Spend $1 Billion On New Factory To Make U.S. Supplies Of Cancer Drug Keytruda- WSJ - marketscreener.com
Exclusive | Merck to Spend $1 Billion on New Factory to Make U.S. Supplies of Blockbuster Drug - WSJ
Merck Set To Add Perioperative Head-And-Neck Cancer To Keytruda Label - insights.citeline.com
Merck & Co. CMO Eliav Barr Assures On Pipeline As Keytruda LOE Looms Large - insights.citeline.com
Merck acquires SpringWorks Therapeutics in multibillion dollar deal - The American Bazaar
Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion - Benzinga
Merck Co Inc Azioni (MRK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):